Fig. 1: [99mTc]NM-01 uptake in NSCLC demonstrates intertumoural heterogeneity. | British Journal of Cancer

Fig. 1: [99mTc]NM-01 uptake in NSCLC demonstrates intertumoural heterogeneity.

From: PD-L1 imaging with [99mTc]NM-01 SPECT/CT is associated with metabolic response to pembrolizumab with/without chemotherapy in advanced lung cancer

Fig. 1

Baseline attenuation corrected and fused axial [18F]FDG PET/CT (left) and [99mTc]NM-01 SPECT/CT (right) images (a–d) in a 63 year old male with PD-L1 positive metastatic NSCLC (PD-L1 TPS 100%, biopsy from station 2 R lymph node). a [18F]FDG PET/CT showing 2 R node with SUVmax 25.2 (white arrow) and T5 vertebra metastasis SUVmax 14.3 (pink arrow). b [99mTc]NM-01 SPECT/CT with 2 R node T:BP of 3.88 (white arrow) and T5 vertebra metastasis T:BP 6.08 (pink arrow). c [18F]FDG PET/CT showing subcarinal node metastasis with SUVmax 29.9 (white arrow) and left hilar primary lesion SUVmax 29.6 (pink arrow). d [99mTc]NM-01 SPECT/CT with subcarinal node metastasis with T:BP of 2.38 (white arrow) and left hilar primary lesion with T:BP of 3.07. e Interlesional heterogeneity of baseline [99mTc]NM-01 T:BP within individual patients according to lesion location and size (mm), as determined with baseline CT imaging. f Bar chart showing the difference (%) between the [99mTc]NM-01 T:BP of both the maximum (dark green) and minimum (light green) metastases from the primary tumour in all patients, with a ± 25% difference between the primary and at least one metastasis in 100% (n = 15) patients, and ± 50% difference in 67% (n = 10).

Back to article page